Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:07:27.685Z.
Calculation as of: 2026-10-06T15:07:27.685Z.
Quote observation: 2026-10-06T15:05:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f4beac4ac45f8a46ab4983c5a571fa9813be082d6d81805b5cbd768b9d0a60c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$5.84M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.68M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.57M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.10M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucyd, Inc (LUCY) | $5.80M | N/A | N/A | N/A | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.84M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.68M | N/A | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.99M | N/A | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.57M | N/A | N/A | N/A | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | N/A | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.17M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.27M | N/A | 96.60x | 88.71x | 504.98x |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.26M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
